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Abstract
Introduction: Atrial fibrillation (AF) is the most common arrhythmia and leads
to a five-fold increased risk of stroke compared to persons with sinus rhythm.
A soluble form of thrombomodulin (sTM) is a recognized marker of endothelial
dysfunction and may contribute to the hypercoagulable state in AF. The aim of
the study was to evaluate plasma concentration of sTM in persistent AF patients
before and after sinus rhythm recovery following direct current cardioversion
(CV). 
Material and methods: In 45 effectively anticoagulated consecutive patients,
with persistent non-valvular AF, and normal left ventricular function, CV was
performed. Blood samples for sTM assessment were collected twice: 24 hours
before and 24 hours after CV. 
Results: In 43 patients sinus rhythm was obtained. The mean plasma sTM level
was significantly lower in AF patients compared to the control group with sinus
rhythm and without anticoagulation (38.5 ±9.9 ng/ml vs. 44.1 ±9.1 ng/ml, 
p = 0.04). Plasma sTM levels did not change 24 hours after successful CV 
(36.7 ±9.5 ng/ml vs. 38.5 ±9.9 ng/ml, p = 0.16). 
Conclusions: Plasma sTM concentration was lower in patients with persistent
AF and normal left ventricle systolic function than in patients with sinus rhythm,
presumably due to chronic oral anticoagulant therapy in the AF group. CV has
no impact on sTM plasma level evaluated 24 hours after sinus rhythm
restoration. 
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Introduction 
Atrial fibrillation (AF) is the most common arrhythmia, affecting > 5%
of the population > 65 years of age, with a prevalence that doubles with
every decade of life [1]. The most important problem with AF is the risk of
stroke. Patients with AF have a five-fold increased risk of stroke compared
to those in sinus rhythm [2]. The loss of mechanical atrial contraction leads
to altered blood flow characteristics that can result in clot formation, almost
exclusively in the left atrial appendage. Recently it has been reported that
AF is accompanied by a hypercoagulable state that may contribute to the
development of atrial thrombi and thromboembolism [3-10]. The
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mechanisms responsible for this hypercoagulable
state remain undefined. However, increased
thrombogenesis, abnormal haemostasis, fibrinolysis
and platelet functions, and atrial and arterial
endothelial damage or dysfunction, could contribute
to the hyper  coagulable state in AF [3-10].
Randomized controlled trials have convincingly
demonstrated that the risk of AF-associated
thromboembolic events (predominantly strokes)
can be reduced by 64% by therapy with vitamin K
antagonists [11]. Direct current cardioversion (CV)
of AF can be associated with a transient mechanical
dysfunction of the left atrium (“atrial stunning”).
Increased atrial stasis connected with abnormal
haemostasis would fulfil components of Virchow’s
triad leading to the development of atrial thrombus
and thrombo  embolism. Soluble thrombomodulin
(sTM), among other endothelial plasma indexes
(e.g. von Willebrand factor, nitrate/nitrite product
NOx, soluble E-selectin), is considered to be
a plasma endothelial damage or dysfunction
marker. However, sTM is a natural anticoagulant on
the membranes of endothelial cells which acts as
a receptor for thrombin [12]. Therefore, the TM
protein C complex plays a crucial role in maintaining
normal blood fluidity and preventing intravascular
thrombosis [12]. The aim of the present study 
was to investigate whether persistent AF in
anticoagulated patients creates a prothrombotic
state, whether CV itself causes endothelial damage
and leads to increase of sTM, or if sinus rhythm
restoration causes changes in sTM levels. 
Material and methods
Direct current CV was performed in 45
consecutive patients with persistent non-valvular
AF with normal left ventricular ejection fraction
(LVEF) in echocardiographic examinations (≥ 50%).
In all patients, left ventricular ejection fraction (LVEF)
and left atrial (LA) diameter were assessed 
by echocardiography examinations before CV. 
The procedure was unsuccessful in 2 cases. 
Finally 43 patients (35 men and 8 women, aged 59
±11.8 years) were included in the study. Patients in
the study group had normal blood pressure, no
symptoms of heart failure and they had preserved
left ventricular systolic function. The control group
comprised 20 patients with sinus rhythm, without
a history of AF and not undergoing anticoagulation
therapy. They were compatible in age and gender,
and they did not differ from the study group in
baseline clinical (hypertension, coronary disease or
diabetes) and echocardiographic data. All AF
patients were scheduled for electrical CV and they
received an oral anticoagulant (acenocoumarol) for
at least 4 weeks (international normalized ratio,
INR, between 2.0 and 3.0) before admission.
Pharmacological therapy was continued before and
after CV. CV was performed under intravenous
general anaesthesia (fentanyl 0.05-0.1 mg,
etomidate 0.2 mg/kg). CV was performed by
delivering R wave synchronized biphasic shocks
with a Medtronic Physio-Control Lifepak 12 external
defibrillator. The initial shock energy was 100 J, 
with a subsequent increment to 200 J and a further
200 J in the event of CV failure. Sinus rhythm
maintenance was assessed in all patients on the
30th day following CV on the basis of an
electrocardiogram and the patients’ medical history
during the previous month. Blood samples for
plasma sTM assessment were collected in the
morning, from the cubital vein twice: 24 hours
before and 24 hours after CV. All specimens were
collected in tubes containing EDTA (ethylene  -
diaminetetraacetic acid) 1.5 g/l. The plasma was
separated by centrifugation (at 2500 rpm) for 
20 min at 4°C and stored at –20°C until
measurement. Soluble TM was determined using
enzyme-linked immunosorbent assay (nanograms
per millilitre; Diagnostica Stago). Inter- and intra-
assay coefficients of variation were 5% and 7%
respectively.
All values are expressed as mean ± standard
deviation. The paired Student’s t test was used to
compare values before and after CV. The Pearson
correlation coefficient was used to determine the
correlation between continuous variables. A p value
< 0.05 was considered statistically significant. All
analyses were performed using the Med Calc
program, version 4.16 g.
Results
Study population characteristics
The clinical characteristics of the study
population were typical for patients with persistent
AF who are referred for CV. The majority of them
were men (81%) with a history of hypertension
(63%). Symptomatic coronary artery disease was
diagnosed in 19% of patients and 7% of the study
group suffered from diabetes (some of the patients
had more than one of the above-mentioned
conditions). Patients with lone AF constituted 20%
of the study population. The mean AF duration was
12.3 ±15.3 weeks. Echocardiographic examination
of patients included in the study revealed moderate
atrial dilatation (43.7 ±5.9 mm). Mean LVEF assessed
by echocardiography was in the normal range 
(57.3 ±6.1%). Plasma NT-proANP level in patients
with persistent AF was 4.8 ±2.9 nmol/l, and 2.8 
±1.2 nmol/l, p = 0.004 in the control group. 
All patients were effectively anticoagulated (INR
2.0-3.0; mean 2.43 ±0.4). The baseline charac  -
teristics of the study population are listed in table I.
All patients who had successful CV (mean energy
delivered was 193 ±62 J) remained in sinus rhythmArch Med Sci 6, December / 2010 889
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until hospital discharge. Due to sinus rhythm
maintenance on the 30th day following CV, patients
were divided into two subgroups: group A
comprised 24 patients (56%) maintaining sinus
rhythm during 30 days following CV, and group B
consisted of 19 patients (44%) with recurrent AF.
There were no significant differences between the
two subgroups in clinical and echocardiographic
baseline characteristics, or in antiarrhythmic
therapy after CV.
Plasma soluble thrombomodulin levels 
in persistent AF patients
The mean baseline plasma sTM level was
significantly lower in patients with persistent
arrhythmia compared to the control group with
sinus rhythm and no history of AF, 38.5 ±9.9 ng/ml
vs. 44.1 ±9.1 ng/ml, p = 0.04 (Figure 1). There was
no correlation between clinical (age, duration of AF,
body mass index, heart rate, blood pressure) and
echocardiographic data and plasma sTM level.
Plasma sTM levels did not change in 24 hours after
successful CV (36.7 ±9.5 ng/ml vs. 38.5 ±9.9 ng/ml,
p = 0.16) (Figure 2). Plasma sTM levels before CV
did not differ significantly between the sinus rhythm
subgroup A and the AF recurrence subgroup B 
(39.3 ±10.3 ng/ml vs. 37.4 ±9.3 ng/ml, p = 0.53).
Discussion
The paper presents the results of a study
evaluating sTM concentration in the blood in patients
with persistent AF and after the recovery of sinus
rhythm. The soluble form of thrombomodulin is one
of the best known endothelium damage factors. The
research conducted in the group of patients with AF
indicates that haemodynamic disorders connected
with arrhythmia lead to significant dysfunction of
the endothelial cells, both in the heart cavities and
in the vessels [4, 8]. In patients with AF, an
increased sTM concentration might be anticipated.
In patients with AF who do not use oral
anticoagulants, increased sTM concentration has
been observed in the course of arrhythmia [3, 8]. In
the present study the sTM concentration in patients
with persistent AF was significantly lower than in
the patients from the control group. The lower 
sTM concentration in patients with persistent 
AF is probably the result of long-term use of
anticoagulants (vitamin K antagonists), which, apart
from the influence they have on plasma coagulation
factors, also inhibit the function of thrombocytes
Parameter Study group, n = 43
x ± SD
Age [years] 59.0 ±11.6
Gender, n (%) 
women 8 (18.6)
men 35 (81.4)
BMI [kg/m2], n (%)
normal (BMI < 25) 5 (11.6)
verweight (BMI 25-29) 19 (44.2)
obesity (BMI ≥ 30) 19 (44.2)
HR (beats/min) 85.4 ±13.0
Systolic BP [mmHg] 130.6 ±14.9
Diastolic BP [mmHg] 80.3 ±9.0
Hypertension, n (%) 27 (62.8)
Coronary artery disease, n (%) 8 (18.6)
Diabetes, n (%) 3 (7.0)
Lone AF, n (%) 9 (20.9)
AF duration [weeks] 12.3 ±15.3
LVEF [%] 57.3 ± 6.1
LA dimension [mm] 43.7 ±5.9
Table I. Study group characteristics
BMI – body mass index, HR – heart rate, BP – blood pressure, AF – atrial
fibrillation, LVEF – left ventricular ejection fraction, LA – left atrium
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Figure 1. Plasma sTM levels in 43 patients with
persistent atrial fibrillation and in the control group
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Figure  2.  Plasma sTM levels before and after
successful cardioversion in 43 patients with
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and hinder the activity of the endothelium [13].
Ikuma et al. [14] noted that long-term therapy with
oral anticoagulants leads to lower sTM
concentrations in the blood. 
Li-Saw-Hee et al. [9] discovered that sTM plasma
concentration in patients with persistent AF who
do not use oral anticoagulants (vitamin K
antagonists) is significantly higher than in control
group patients with sinus rhythm. The same
authors stated, on the basis of a study of patients
with persistent AF with concomitant mitral stenosis
(with long-term use of warfarin – INR on average
1.7), that the sTM concentration was significantly
lower in comparison to the control group of healthy
volunteers with normal sinus rhythm [15]. Freestone
et al. [16], examining markers of endothelial
damage (von Willebrand factor and sTM) before and
after CV, did not observe increased sTM plasma
concentrations in persistent AF before CV. At the
same time, Marin et al. [3] discovered that sTM
concentrations in patients with both paroxysmal
and persistent AF are significantly higher than in
patients with stable coronary disease with sinus
rhythm. Attention should be paid to the fact that
in that study neither group of patients had used
oral anticoagulants for a significant amount of time,
and they were administered antiplatelet drugs only. 
Finally, Freestone et al. [17] studied 145 patients
with AF (paroxysmal, persistent and permanent)
and 35 patients with lone AF. Plasma levels of sTM
measured by ELISA tests were compared to 40
healthy control subjects in sinus rhythm. Plasma
levels of sTM in patients with AF were not
significantly different (control group: 43 ng/ml vs.
AF group: 31 ng/ml, p = 0.119). There were no
differences among the clinical subgroups of
patients with paroxysmal, persistent and
permanent AF. Patients with lone AF had
significantly lower sTM concentration compared to
the control group. Plasma sTM level did not differ
significantly among patients with AF after 4 weeks
of warfarin treatment. 
In our study plasma sTM concentration was
lower in patients with persistent AF than in control
patients with sinus rhythm. The slightly lower sTM
levels in AF patients may be associated with the
presence of an extrinsic anticoagulant (i.e. a vitamin
K antagonist which could alter the expression of
this physiological anticoagulant by reducing
thrombin formation) or could alternatively be due
to the downregulation of thrombomodulin as
a result of early endothelial dysfunction. Takeshi et
al. [18] revealed that rapid atrial pacing significantly
reduced gene expression of TM in the left atrium.
Immunohistochemical analysis showed that TM
was expressed predominantly in the normal atrial
endocardium, presumably preventing local blood
coagulation. Rapid atrial pacing downregulated the
gene expression in the endocardium, leading to
deficiency in anticoagulant barriers. In the
examined group of patients with persistent AF
there was no association between the basal sTM
plasma concentration and the age of patients,
duration of AF, body mass index, heart rate, blood
pressure and echocardiographic data. In contrast,
Mondillo et al. [4] in a group of patients with lone
AF, who did not undergo anticoagulation, reported
slightly higher values of sTM than in the controls,
and observed a positive linear correlation between
left atrial volume and markers of endothelial
dysfunction (sTM and von Willebrand factor). 
Improved function of the endothelium within the
heart cavities could be associated with the
stabilization of the heart rhythm and improved
mechanical heart function after CV. As the recovery
of haemodynamic atrial function does not happen
directly after CV, it can be assumed that the main
factor influencing sTM concentrations after
arrhythmia regression is the stabilization of heart
rhythm. On the other hand, as CV is connected with
analgesia and the use of electric current, the effect
of the procedure itself on the endothelial
dysfunction directly after the recovery of sinus
rhythm cannot be excluded. The damage of the
endothelium may take place during CV, which could
intensify the hypercoagulability state. Although
changes in plasma sTM levels might be expected,
no statistically significant changes after the
recovery of sinus rhythm, in the first 24 hours after
CV, were observed in our study. Our findings are in
accordance with the study of Freestone et al. [16].
They concluded that concentrations of plasma sTM
and other endothelial markers (von Willebrand
factor, soluble E-selectin, nitrate/nitrite products)
did not significantly increase after successful CV.
All patients were therapeutically anticoagulated in
our study and in that of Freestone et al. [16].
Analysing the endothelial damage markers before
and after CV, the authors stated that the expression
of endothelial dysfunction can be attenuated by
the effect of long-term acenocoumarol use. This is
a further reason for the necessity to resort to
effective anticoagulation in AF patients during
a period of at least 4 weeks after the recovery of
sinus rhythm. 
Persistent atrial fibrillation in efficiently
anticoagulated patients is not associated with
higher thrombomodulin levels, in comparison 
to the control group. Successful CV does not 
lead to significant changes in thrombomodulin
concentration in a period of 24 hours after CV. 
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